|Table of Contents|

Effect of modified Miccoli minimally invasive surgery on differentiated thyroid cancer and analysis of related influencing factors

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 05
Page:
777-783
Research Field:
Publishing date:

Info

Title:
Effect of modified Miccoli minimally invasive surgery on differentiated thyroid cancer and analysis of related influencing factors
Author(s):
SONG Chunfeng; LIU Manxiang; WANG Cao; SUN Yang; ZHANG Lu; GUO Man; LI Weihan; SONG Zonggong
Nanyang Central Hospital,Henan Nanyang 473000,China.
Keywords:
differentiated thyroid carcinoma; modified Miccoli minimally invasive surgery; therapeutic effect; recurrence; influencing factor
PACS:
R736.1
DOI:
10.3969/j.issn.1672-4992.2025.05.009
Abstract:
Objective:To investigate the effect and related influencing factors of modified Miccoli minimally invasive surgery for differentiated thyroid cancer(DTC).Methods:A total of 160 DTC patients who received modified Miccoli minimally invasive surgery from January 2020 to December 2022 were selected as the improved group,and 80 DTC patients who underwent traditional thyroidectomy during the same period were selected as the routine group.The operation status and one-year postoperative recurrence rate of the two groups were compared.Lasso regression analysis and Logistic regression analysis were used to analyze the influencing factors of postoperative recurrence.Results:The operation time,incision length,and hospitalization days in the modified group were shorter than those in the conventional group,the intraoperative blood loss was less than that in the conventional group,the complication rate was lower than that in the conventional group,and the incision aesthetics score and patient satisfaction score for incision scars were higher than those in the conventional group(P<0.05).One year after surgery,3 cases were lost to follow-up,and a total of 237 DTC patients completed follow-up.Among the 237 DTC patients,40 cases were recurrent,with a recurrence rate of 16.88%(40/237).Among them,158 patients in the modified group who completed follow-up had 15 cases of recurrence at one year after surgery,with a recurrence rate of 9.49%.Among the 79 patients in the conventional group who completed follow-up,25 cases were recurrent at one year after surgery,with a recurrence rate of 31.65%.The recurrence rate in the modified group was lower than that in the conventional group(P<0.05).Univariate analysis showed that age,tumor diameter,lesion type,pathological type,TNM stage,lymph node metastasis,postoperative 131I therapy,postoperative triiodothyronine(T3),thyroxine(T4),and thyroid stimulating hormone(TSH) were the influencing factors for postoperative recurrence in patients with DTC(P<0.05).Lasso regression analysis screened out 8 factors:Tumor diameter,TNM stage,lymph node metastasis,surgical approach,postoperative 131I therapy,postoperative T3,T4,and TSH.Logistic regression analysis showed that tumor diameter,TNM stage Ⅲ-Ⅳ,lymph node metastasis,postoperative T3,T4,and TSH were independent risk factors for postoperative recurrence in patients with DTC.Modified Miccoli minimally invasive surgery and postoperative 131I therapy were independent protective factors for postoperative recurrence in patients with DTC(P<0.05).Conclusion:The application of the modified Miccoli minimally invasive surgery for DTC patients can significantly optimize the surgical conditions,reduce complications,improve the aesthetic appearance of the incision,and reduce the recurrence rate.The tumor diameter,TNM staging,lymph node metastasis,surgical approach,postoperative 131I therapy,postoperative T3,T4,and TSH are factors that affect postoperative recurrence.

References:

［1］SCHLUMBERGER M,LEBOULLEUX S.Current practice in patients with differentiated thyroid cancer［J］.Nat Rev Endocrinol,2021,17(3):176-188.
［2］CIARALLO A,RIVERA J.Radioactive iodine therapy in differentiated thyroid cancer:2020 Update［J］.AJR Am J Roentgenol,2020,215(2):285-291.
［3］BAKKAR S,PAPAVRAMIDIS TS,ALJARRAH Q,et al.Energy-based devices in thyroid surgery-an overview［J］.Gland Surg,2020,9(Suppl 1):S14-S17.
［4］穆慧君,齐宝珍,刘祯.改良Miccoli术式内镜甲状腺手术治疗对早期分化型甲状腺癌患者的疗效与分析［J］.实用癌症杂志,2023,38(9):1554-1557. MU HJ,QI BZ,LIU Z.The efficacy and analysis of modified Miccoli's endoscopic thyroid surgery for early differentiated thyroid cancer patients［J］.Journal of Practical Cancer,2023,38(9):1554-1557.
［5］HESCOT S,AL GHUZLAN A,HENRY T,et al.Prognostic of recurrence and survival in poorly differentiated thyroid cancer［J］.Endocr Relat Cancer,2022,29(11):625-634.
［6］KUDELKA MR,LASANAJAK Y,SMITH DF,et al.Serum glycomic profile as a predictive biomarker of recurrence in patients with differentiated thyroid cancer［J］.Cancer Med,2023,12(6):6768-6777.
［7］The Endocrinology Branch of the Chinese Medical Association,the Thyroid and Metabolic Surgery Group of the Surgery Society of the Chinese Medical Association,and the Head and Neck Tumor Professional Committee of the Chinese Anti Cancer Association Diagnosis and Treatment.Guidelines for thyroid nodules and differentiated thyroid cancer(second edition)［J］.Chinese Journal of Endocrine Metabolism,2023,39(3):181-226.
［8］LEE H,KIM TS,GU JY,et al.Value of circulating neutrophil elastase for detecting recurrence of differentiated thyroid cancer［J］.Endocr Connect,2023,12(12):e230400.
［9］潘晓培,钱连连,王慧慧.改良Miccoli手术治疗分化型甲状腺癌的临床效果及术后复发的相关影响因素［J］.实用癌症杂志,2023,38(1):73-75. PAN XP,QIAN LL,WANG HH.The clinical efficacy of modified Miccoli surgery in the treatment of differentiated thyroid cancer and the related influencing factors of postoperative recurrence［J］.Journal of Practical Cancer,2023,38(1):73-75.
［10］覃丰毅,游波.改良Miccoli手术治疗cN0期甲状腺乳头状癌的临床研究［J］.微创医学,2021,16(2):200-203. QIN FY,YOU B.Clinical study on modified Miccoli surgery for the treatment of cN0 stage papillary thyroid carcinoma［J］.Minimally Invasive Medicine,2021,16(2):200-203.
［11］CHEN WN,LI J,PENG S,et al.Association of total thyroidectomy or thyroid lobectomy with the quality of life in patients with differentiated thyroid cancer with low to intermediate risk of recurrence［J］.JAMA Surg,2022,157(3):200-209.
［12］COLOMBO C,DE LEO S,DI STEFANO M,et al.Total thyroidectomy versus lobectomy for thyroid cancer:Single-center data and literature review［J］.Ann Surg Oncol,2021,28(8):4334-4344.
［13］YAN CM.Professor Paolo Miccoli:Robotic surgery will become more and more popular［J］.Gland Surg,2016,5(6):652-653.
［14］魏勇军,张文娟,詹斌,等.改良Miccoli手术在甲状腺癌治疗中的应用［J］.腹腔镜外科杂志,2022,27(11):806-809. WEI YJ,ZHANG WJ,ZHAN B,et al.The application of improved Miccoli surgery in the treatment of thyroid cancer［J］.Journal of Laparoscopic Surgery,2022,27(11):806-809.
［15］汪鑫,武晓娜,曹力钒,等.改良Miccoli手术治疗分化型甲状腺癌的疗效及术后复发的相关因素分析［J］.癌症进展,2020,18(2):172-175. WANG X,WU XN,CAO LF,et al.The efficacy of modified Miccoli surgery in the treatment of differentiated thyroid cancer and analysis of related factors for postoperative recurrence［J］.Cancer Progression,2020,18(2):172-175.
［16］RUGIU MG,MIANI C,LOCATELLO LG.Total or partial thyroidectomy for low-risk differentiated thyroid cancer:That is the question［J］Acta Otorhinolaryngol Ital,2022,42(5):487-489.
［17］LYU DP,XIAO HN,YANG YL,et al.Surgical efficacy and prognosis analysis of modified Miccoli surgery and low incision surgery for thyroid adenoma［J］.Journal of North Sichuan Medical College,2020,35(1):82-84.
［18］MANIAM P,ISHII H,STECHMAN MJ,et al.A study of variation in therapeutic approach to low-risk differentiated thyroid cancer in the UK［J］.J Laryngol Otol,2024,138(1):83-88.
［19］XU SY,HUANG H,QIAN JX,et al.Prevalence of hashimoto thyroiditis in adults with papillary thyroid cancer and its association with cancer recurrence and outcomes［J］.JAMA Netw Open,2021,4(7):e2118526.
［20］SAN JUAN MD,PAZ-PACHECO E.Incidence,recurrence and mortality among filipinos with differentiated thyroid cancer:A systematic review［J］.J ASEAN Fed Endocr Soc,2023,38(1):100-107.
［21］JANKOVIC MILJUS J,GUILLEN-SACOTO MA,MAKIADI-ALVARADO J,et al.Circulating microRNA profiles as potential biomarkers for differentiated thyroid cancer recurrence［J］.J Clin Endocrinol Metab,2022,107(5):1280-1293.
［22］PAYGA I,RUMIAN M,KOSEL A,et al.The frequency of differentiated thyroid cancer recurrence in 2302 patients with excellent response to primary therapy［J］.J Clin Endocrinol Metab,2024,109(2):e569-e578.
［23］PATTI L,GAY S,MUSSO L,et al.Impact of microscopic extrathyroidal extension on differentiated thyroid cancer post-surgical risk of recurrence:A retrospective analysis［J］.J Endocrinol Invest,2023,46(10):2157-2164.
［24］ELBASAN O,GOGAS YAVUZ D.Comparison of staging and recurrence predictors in patients with differentiated thyroid cancer between the 7th and 8th editions of the American Joint Committee on Cancer staging systems［J］.Minerva Endocrinol(Torino),2023,48(3):261-273.
［25］CAVALHEIRO BG,SHAH JP,RANDOLPH GW,et al.Management of recurrent well-differentiated thyroid carcinoma in the neck:A comprehensive review［J］.Cancers(Basel),2023,15(3):923.
［26］GAO HY,HUANG JY,DAI QJ,et al.Radioiodine(131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer［J］.Arch Endocrinol Metab,2023,67(2):197-205.
［27］JIANG S,YU M,WANG HY,et al.131I-radioisotope modified in PEGylation metal organic frameworks for sensitization in refractory differentiated thyroid cancer treatment［J］.J Biomater Appl,2021,36(5):851-858.
［28］WON HR,JEON E,CHANG JW,et al.Is maintaining thyroid-stimulating hormone effective in patients undergoing thyroid lobectomy for low-risk differentiated thyroid cancer?A systematic review and Meta-analysis［J］.Cancers(Basel),2022,14(6):1470.

Memo

Memo:
河南省医学科技攻关计划项目（编号：LHGJ20210977）
Last Update: 1900-01-01